Blocking the PD-1/PD-L1 pathway using PD-1 monoclonal antibodies can significantly enhance the killing effect of autologous T cells, NK cells, and monocytes/macrophages on multiple myeloma cells. This evidence concerns the gene CD274 and AL amyloidosis.